Valcon Medical II

Providing alternatives for chronic pain with medicinal cannabis.

Investment overview

Impact category

Social economy

Investment type

Loan

Yearly interest

7.1

Term

months

Risk level

What will you be financing?

Valcon Medical A/S is a Danish company specializing in the manufacturing of medical cannabis extracts. Valcon's mission is to provide patients with access to alternative medications that positively impact health issues such as chronic pain, epilepsy, and other serious conditions. The use of medical cannabis is helping to decrease opioid use, offering a safer option for pain management and tackling the opioid crisis.

To capitalize on the growing demand and expand its product portfolio and distribution network, the promoter first raised 300.000€ through the campaign Valcon Medical. The goal is to raise another 250.000€ to continue delivering high-quality, therapeutic cannabis solutions to patients across Europe. The funds raised in the campaign will be used to:

Expansion of Product Portfolio
Manufacturing Capabilities
Product Development
Technology Upgrades
Operational Expansion

In recent years, Europe has experienced a historic shift in policy as countries increasingly recognize the medical benefits of cannabis. This transformative change is opening up new markets, and providing opportunities for innovation and investment in the medical cannabis sector.

What is the impact?

Direct

Offering of safe, effective and quality medicines for health-care and human well-being: Valcon Medical manufactures medicinal cannabis products that enhance human well-being, providing alternative treatments for chronic pain, epilepsy, and other conditions where conventional medicines may fail Their products improve symptom management and reduce dependence on addictive opioids.
Medical cannabis treats conditions like chronic pain, multiple sclerosis (MS), epilepsy, Spinal cord injury and cancer-related symptoms. It is an option for patients who experience a lack of efficacy or poor tolerance to conventional medicine, and often complements current medication for managing pain, muscle spasms, seizures, and nausea.
Promotion of innovation and entrepreneurship: a relevant portion of the funding is dedicated to developing a new product format for the European medical cannabis market – a medical cannabis vaporization and inhalation devices, which provide rapid relief for breakthrough pain. Valcon Medical will invest in advanced extraction technologies to improve the efficiency and yield of cannabis extracts, ensuring that the extracts maintain high potency and purity, crucial for medical applications. By being one of the first to introduce medical cannabis inhalation products in Europe, Valcon Medical positions itself as an industry innovator, setting a benchmark for others and driving industry progress.

Indirect

Implementation of sustainable practices of consumption and production: Valcon Medical, certified by the ISO 14001 for environmental management systems (EMS), implements a strategy for environmental sustainability at the company’s activities level and similar can be found at their supplier. The company uses energy from Danish renewable sources and, in the production, implements efficient extraction technologies that reduce resources consumption and waste. The promoter prioritizes the use of environmentally friendly solvents in extraction processes which are less harmful to the environment and contribute to safer working conditions. At their primary supplier, Schroll Medical, they implement sustainable agricultural practices: reduced or no synthetic pesticides and fertilizers; efficient water use with efficient techniques like drip irrigation and water recycling in the cultivation; energy efficiency through LED lighting and use of renewable energy from their own solar system; crop rotation and composting; biodegradable and recyclable packaging materials; and prioritization of local suppliers.
Promotion of community awareness and advocacy: Valcon Medical is actively involved in policy advocacy to shape effective public policies and access regarding medical cannabis in Denmark and across Europe. Also, the company invests in community outreach programs to educate the public about the benefits and safe use of medical cannabis.
Creation of jobs: with this funding for the company’s growth, Valcon Medical foresees hiring 10 people during the loan’s two years as permanent positions medical production professionals and regulatory specialists.

Impact indicators
‍

CO2 avoided per year

clean energy

created by our projects

of sustainable

impacted

Contribution to the Sustainable Development Goals
‍

About the Promoter

About

Valcon Medical A/S

Direct

Offering of safe, effective and quality medicines for health-care and human well-being: Valcon Medical manufactures medicinal cannabis products that enhance human well-being, providing alternative treatments for chronic pain, epilepsy, and other conditions where conventional medicines may fail Their products improve symptom management and reduce dependence on addictive opioids.
Medical cannabis treats conditions like chronic pain, multiple sclerosis (MS), epilepsy, Spinal cord injury and cancer-related symptoms. It is an option for patients who experience a lack of efficacy or poor tolerance to conventional medicine, and often complements current medication for managing pain, muscle spasms, seizures, and nausea.
Promotion of innovation and entrepreneurship: a relevant portion of the funding is dedicated to developing a new product format for the European medical cannabis market – a medical cannabis vaporization and inhalation devices, which provide rapid relief for breakthrough pain. Valcon Medical will invest in advanced extraction technologies to improve the efficiency and yield of cannabis extracts, ensuring that the extracts maintain high potency and purity, crucial for medical applications. By being one of the first to introduce medical cannabis inhalation products in Europe, Valcon Medical positions itself as an industry innovator, setting a benchmark for others and driving industry progress.

Indirect

Implementation of sustainable practices of consumption and production: Valcon Medical, certified by the ISO 14001 for environmental management systems (EMS), implements a strategy for environmental sustainability at the company’s activities level and similar can be found at their supplier. The company uses energy from Danish renewable sources and, in the production, implements efficient extraction technologies that reduce resources consumption and waste. The promoter prioritizes the use of environmentally friendly solvents in extraction processes which are less harmful to the environment and contribute to safer working conditions. At their primary supplier, Schroll Medical, they implement sustainable agricultural practices: reduced or no synthetic pesticides and fertilizers; efficient water use with efficient techniques like drip irrigation and water recycling in the cultivation; energy efficiency through LED lighting and use of renewable energy from their own solar system; crop rotation and composting; biodegradable and recyclable packaging materials; and prioritization of local suppliers.
Promotion of community awareness and advocacy: Valcon Medical is actively involved in policy advocacy to shape effective public policies and access regarding medical cannabis in Denmark and across Europe. Also, the company invests in community outreach programs to educate the public about the benefits and safe use of medical cannabis.
Creation of jobs: with this funding for the company’s growth, Valcon Medical foresees hiring 10 people during the loan’s two years as permanent positions medical production professionals and regulatory specialists.

Promoter website

https://www.valcon-medical.com/

Team
‍

[{"id":253,"promoter_id":333,"name":"Pete Patterson","description":"Pete Patterson is a seasoned entrepreneur with a proven track record in the cannabis extraction industry, having founded and led Vitalis Extraction Technology to significant success. His dedication to medical cannabis stems from a personal experience where a family member's use of cannabis for chronic pain management led to life-changing results.","link":"https://www.linkedin.com/in/pete-patterson/","role":"CEO","member_photo":"https://991934249232-prod-octobercms-public-storage.s3.eu-west-1.amazonaws.com/public/66b/5fb/197/66b5fb19789fb630616891.png","avatar_id":149869},{"id":254,"promoter_id":333,"name":"Peter Sigetty","description":"Peter Sigetty is an innovative entrepreneur and thought leader in the medical cannabis industry, known for his cultivation, extraction, and regulatory compliance expertise. His passion for medical cannabis is deeply personal, driven by witnessing its transformative effects on a family member suffering from chronic pain.","link":"https://www.linkedin.com/in/peter-emil-sigetty-830602224/","role":"COO","member_photo":"https://991934249232-prod-octobercms-public-storage.s3.eu-west-1.amazonaws.com/public/66b/5fa/ce2/66b5face2441f337857933.jpg","avatar_id":149864},{"id":255,"promoter_id":333,"name":"Helena Christensen","description":"Helena Christensen is a respected advocate for the standardization and quality control of medical cannabis extracts, leveraging her extensive background in pharmaceutical sciences. Her commitment to improving patient care through high-quality cannabis products is evident in her active research, advocacy, and policy-making involvement.","link":"https://www.linkedin.com/in/helena-christensen-cannabis/","role":"Medical Affairs Manager","member_photo":"https://991934249232-prod-octobercms-public-storage.s3.eu-west-1.amazonaws.com/public/66b/5fa/be9/66b5fabe97ef1321542518.png","avatar_id":149862}]

Business Model
‍

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.